{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:32:25Z","timestamp":1793712745609,"version":"4.6.1"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Noninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment of noninfectious uveitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>The HUMBOLDT trial was a double-masked, placebo-controlled, phase 2, randomized clinical trial conducted from July 2017 to April 2021 at 26 centers in 7 countries. Eligible participants (aged \u226518 years) had active noninfectious intermediate uveitis, posterior uveitis, or panuveitis despite at least 2 weeks of treatment with oral prednisone (10-60 mg per day).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants were randomly assigned 1:1 to receive filgotinib, 200 mg, or placebo orally once daily for up to 52 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end point was the proportion of participants experiencing treatment failure by week 24. Treatment failure was a composite end point represented by assessment of the presence of chorioretinal and\/or retinal vascular lesions, best-corrected visual acuity, and anterior chamber cell and vitreous haze grades. Safety was assessed in participants who received at least 1 dose of study drug or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between July 26, 2017, and April 22, 2021, 116 participants were screened, and 74 (mean [SD] age, 46 [16] years; 43 female [59.7%] of 72 participants, as 2 participants did not receive treatment doses) were randomly assigned to receive filgotinib (n\u2009=\u200938) or placebo (n\u2009=\u200936). Despite early termination of the trial for business reasons ahead of meeting enrollment targets, a significantly reduced proportion of participants who received filgotinib experienced treatment failure by week 24 vs placebo (12 of 32 participants [37.5%] vs 23 of 34 participants [67.6%]; difference vs placebo \u221230.1%; 95% CI, \u221256.2% to \u22124.1%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.006). Business reasons were unrelated to efficacy or safety. Adverse events were reported in 30 of 37 participants (81.1%) who received filgotinib and in 24 of 35 participants (68.6%) who received placebo. Serious adverse events were reported in 5 of 37 participants (13.5%) in the filgotinib group and in 2 of 35 participants (5.7%) in the placebo group. No deaths were reported during the trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Results of this randomized clinical trial show that filgotinib lowered the risk of treatment failure in participants with active noninfectious intermediate uveitis, posterior uveitis, or panuveitis vs placebo. Although the HUMBOLDT trial provided evidence supporting the efficacy of filgotinib in patients with active noninfectious uveitis, the premature termination of the trial prevented collection of additional safety or efficacy information of this JAK1 preferential inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03207815\">NCT03207815<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.2439","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T11:03:33Z","timestamp":1721300613000},"page":"789","source":"Crossref","is-referenced-by-count":36,"title":["Filgotinib in Active Noninfectious Uveitis"],"prefix":"10.1001","volume":"142","author":[{"given":"Sunil K.","family":"Srivastava","sequence":"first","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Watkins","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Stanford University, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Sharma","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Scales","sequence":"additional","affiliation":[{"name":"Retina & Uveitis Consultants of Texas PA, San Antonio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Dacey","sequence":"additional","affiliation":[{"name":"Colorado Retina Associates, Denver"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv E.","family":"Shah","sequence":"additional","affiliation":[{"name":"Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Chu","sequence":"additional","affiliation":[{"name":"Metropolitan Eye Research and Surgery Institute, Palisades Park, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilraj S.","family":"Grewal","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Faia","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants PC, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Suhler","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University and VA Portland Health Care System, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Barchuk","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Besuyen","sequence":"additional","affiliation":[{"name":"Galapagos BV, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Dick","sequence":"additional","affiliation":[{"name":"Bristol Medical School and School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom"},{"name":"National Institute of Health Research Moorfields Biomedical Research Centre, UCL Institute of Ophthalmology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Legacy Devers Eye Institute, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"eoi240040r1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.semarthrit.2019.06.004","article-title":"New observations and emerging ideas in diagnosis and management of noninfectious uveitis: a review.","volume":"49","author":"Rosenbaum","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"eoi240040r2","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis.","volume":"88","author":"Durrani","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"eoi240040r3","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1517\/13543784.2011.617741","article-title":"Road to remission: a comprehensive review of therapy in uveitis.","volume":"20","author":"Siddique","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"eoi240040r4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4103\/0301-4738.114090","article-title":"Uveitis in developing countries.","volume":"61","author":"Rao","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"eoi240040r5","doi-asserted-by":"publisher","first-page":"c4976","DOI":"10.1136\/bmj.c4976","article-title":"Investigation and management of uveitis.","volume":"341","author":"Guly","year":"2010","journal-title":"BMJ"},{"issue":"11","key":"eoi240040r6","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1001\/jamaophthalmol.2013.4237","article-title":"Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study.","volume":"131","author":"Acharya","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"eoi240040r7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.623725","article-title":"Uveitis: molecular pathogenesis and emerging therapies.","volume":"12","author":"Egwuagu","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"eoi240040r8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ophtha.2015.10.028","article-title":"Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis.","volume":"123","author":"Dick","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi240040r9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ophtha.2010.03.029","article-title":"A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the US.","volume":"118","author":"Nguyen","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi240040r10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Antitumor necrosis factor-a therapy in uveitis.","volume":"60","author":"Cordero-Coma","year":"2015","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"eoi240040r13","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis.","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"10050","key":"eoi240040r14","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive noninfectious uveitis controlled by corticosteroids (VISUAL II): a multicenter, double-masked, randomized, placebo-controlled phase 3 trial.","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"eoi240040r17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects.","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"10292","key":"eoi240040r18","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomized, placebo-controlled trial.","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"eoi240040r20","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomized, dose-finding study (DARWIN 2).","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"eoi240040r21","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib vs placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomized clinical trial.","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"eoi240040r22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial.","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"eoi240040r23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomized, dose-finding study (DARWIN 1).","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"eoi240040r24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy vs methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomized controlled FINCH 3 trial.","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"eoi240040r25","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126?815 reports from the WHO pharmacovigilance database.","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"eoi240040r26","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212595","article-title":"Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis.","volume":"8","author":"Biggioggero","year":"2019","journal-title":"Drugs Context"},{"key":"eoi240040r11","unstructured":"AbbVie Inc. Humira (adalimumab) home page. Accessed March 30, 2024. https:\/\/www.humirapro.com"},{"key":"eoi240040r12","unstructured":"European Medicines Agency. Humira (adalimumab) overview. Accessed March 30, 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira"},{"key":"eoi240040r15","unstructured":"Electronic Medicines Compendium. Jyseleca 100-mg film-coated tablets. Accessed March 30, 2024. https:\/\/www.medicines.org.uk\/emc\/product\/11809\/smpc#gref"},{"key":"eoi240040r16","unstructured":"Gilead Sciences. Jyseleca (filgotinib) approved in Japan for rheumatoid arthritis. Accessed March 30, 2024. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/9\/jyseleca-filgotinib-approved-in-japan-for-rheumatoid-arthritis"},{"key":"eoi240040r19","unstructured":"European Medicines Agency. Summary of product characteristics: Jyseleca (filgotinib). Accessed March 30, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jyseleca-epar-product-information_en.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2820954\/jamaophthalmology_srivastava_2024_oi_240040_1726689710.89646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:38:26Z","timestamp":1726749506000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2820954"}},"subtitle":["The HUMBOLDT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2439","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}